BRCA1 and pancreatic neoplasm: POLO (Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy), an ongoing randomized phase 3 study, is investigating olaparib in patients with metastatic BRCA1/2 mutant pancreas cancer as a maintenance strategy following platinum based chemotherapy [65].